Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a product name.
REQUEST A FREE TRIAL
Product
Deals
Articles
BioCentury
|
Oct 21, 2020
Product Development
Aducanumab looms larger after Biogen cuts guidance, shelves programs in MS and SMA
Pressure on aducanumab heats up as Biogen submits an MAA to EMA
Read More
BioCentury
|
Apr 25, 2017
Company News
Biogen climbs as Spinraza sales top consensus
Read More
BioCentury
|
Jan 6, 2017
Finance
Good riddance
Why investors think 2017 will be an up year for biotech despite macro uncertainty
Read More
BioCentury
|
Sep 26, 2016
Clinical News
Opicinumab: Additional Phase II data
Read More
BioCentury
|
Sep 16, 2016
Clinical News
Biogen ties anti-LINGO miss to non-linear dose response
Read More
BioCentury
|
Sep 15, 2016
Targets & Mechanisms
KOR-recting MS
Why the MS field might invest in biased opioid agonists
Read More
BioCentury
|
Jul 11, 2016
Finance
Ground up
How biotech stocks may navigate post-Brexit, pre-election waters
Read More
BioCentury
|
Jul 11, 2016
Finance
Rethinking risk
Investors' top names and milestones in 3Q16
Read More
BioCentury
|
Jun 20, 2016
Product Development
Translating LINGO
Hypotheses about the reasons for Biogen's LINGO miss in MS
Read More
BioCentury
|
Jun 13, 2016
Finance
Bad language
How investors view Biogen after its anti-LINGO came up short in MS
Read More
Items per page:
10
1 - 10 of 43